Loading...
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.
Altenburg, Arwen F van Trierum, Stella E de Bruin, Erwin de Meulder, Dennis van de Sandt, Carolien E van der Klis, Fiona R M Fouchier, Ron A M Koopmans, Marion P G Rimmelzwaan, Guus F de Vries, Rory D
Altenburg, Arwen F
van Trierum, Stella E
de Bruin, Erwin
de Meulder, Dennis
van de Sandt, Carolien E
van der Klis, Fiona R M
Fouchier, Ron A M
Koopmans, Marion P G
Rimmelzwaan, Guus F
de Vries, Rory D
Citations
Altmetric:
Series / Report no.
Open Access
Type
Article
Language
en
Date of publication
2018-04-24
Year of publication
Files
Loading...
s41598-018-24820-2.pdf
Adobe PDF, 1.99 MB
Research Projects
Organizational Units
Journal Issue
Title
Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines.
Translated Title
Published in
Sci Rep 2018; 8(1):6474
Abstract
The replication-deficient orthopoxvirus modified vaccinia virus Ankara (MVA) is a promising vaccine vector against various pathogens and has an excellent safety record. However, pre-existing vector-specific immunity is frequently suggested to be a drawback of MVA-based vaccines. To address this issue, mice were vaccinated with MVA-based influenza vaccines in the presence or absence of orthopoxvirus-specific immunity. Importantly, protective efficacy of an MVA-based influenza vaccine against a homologous challenge was not impaired in the presence of orthopoxvirus-specific pre-existing immunity. Nonetheless, orthopoxvirus-specific pre-existing immunity reduced the induction of antigen-specific antibodies under specific conditions and completely prevented induction of antigen-specific T cell responses by rMVA-based vaccination. Notably, antibodies induced by vaccinia virus vaccination, both in mice and humans, were not capable of neutralizing MVA. Thus, when using rMVA-based vaccines it is important to consider the main correlate of protection induced by the vaccine, the vaccine dose and the orthopoxvirus immune status of vaccine recipients.